Clinical Trials Logo

Epilepsy clinical trials

View clinical trials related to Epilepsy.

Filter by:

NCT ID: NCT04171934 Completed - Epilepsy; Seizure Clinical Trials

Clinical Validation of a Video-based Epilepsy Examination Service

Nelli
Start date: June 17, 2019
Phase:
Study type: Observational [Patient Registry]

The main purpose of this study is to validate the ability of the Nelli system (video-based epilepsy examination system) to detect epileptic motor seizure behaviors in patients at rest.

NCT ID: NCT04169581 Completed - Clinical trials for Epilepsy, Temporal Lobe

A Deep Learning Framework for Pediatric TLE Detection Using 18F-FDG-PET Imaging

Start date: June 1, 2018
Phase:
Study type: Observational

This study aims to use radiomics analysis and deep learning approaches for seizure focus detection in pediatric patients with temporal lobe epilepsy (TLE). Ten positron emission tomograph (PET) radiomics features related to pediatric temporal bole epilepsy are extracted and modelled, and the Siamese network is trained to automatically locate epileptogenic zones for assistance of diagnosis.

NCT ID: NCT04144478 Completed - Epilepsy Clinical Trials

Web-Based Epilepsy Education Program for Adolescents and Parents

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

This study aims to develop a web-based epilepsy education program for adolescents with epilepsy and their parents and to evaluate the efficacy of eb-based epilepsy education program on health management.eb-based epilepsy education program has been proved to be a useful and reliable educational website for the development of knowledge, attitude, self-efficacy and e-health literacy of adolescents with epilepsy and their parents.

NCT ID: NCT04132063 Completed - Epilepsy Clinical Trials

Generic Substitution of Original Levetiracetam in Thai Epilepsy Patients

Start date: November 1, 2018
Phase:
Study type: Observational

The retrospective pre-post observational study was conducted to evaluate the real-world evidence of efficacy and tolerability of generic levetiracetam (oral tablet) which was switched from original levetiracetam (oral tablet) in patients with epilepsy at the national hospital for neurology and neurosurgery in Thailand. Epilepsy patients who received generic substitution to original levetiracetam at the same dose and had stable conditions of seizure were only included. In the period of 6 months, the investigators assessed the change of seizure frequency, the incidence of hospitalization due to breakthrough seizure, the incidence of adverse events and the incidence of composite outcomes related to dosage adjustment of antiepileptic drugs.

NCT ID: NCT04112862 Completed - Epilepsy Clinical Trials

Sodium Lactate Infusion in GLUT1DS Patients

Start date: May 20, 2022
Phase: Early Phase 1
Study type: Interventional

This study investigates the effect of lactate infusion on epileptic discharges on EEG and seizure frequency in glucose transporter 1 deficiency syndrome (GLUT1DS) patients.

NCT ID: NCT04061707 Completed - Epilepsies, Focal Clinical Trials

Subcutaneous EEG: Forecasting of Epileptic Seizures

SUBER
Start date: May 15, 2019
Phase:
Study type: Observational

Protocol Summary Population - Target population is 10 adults (18 to 75 years of age) with a diagnosis of treatment-resistant epilepsy with at least 20 seizures per year, and whose seizure onset recorded from scalp EEG is localized to a brain region accessible by the subcutaneous EEG electrodes Number of sites - Three sites; King's College Hospital NHS Foundation Trust, University College London Hospital NHS Foundation Trust, St George's University Hospital NHS Foundation Trust Study design - This study is an observational, non-randomised, non-interventional study. It is not intended as a device trial. It is not intended to assess the device performance, rather the usefulness of bio-signals in seizure prediction and in detecting seizure-associated phenomena. There will be no change to usual care as a result of taking part. A subcutaneous EEG device will be implanted under local anaesthesia to record continuous EEG and a non-invasive wrist-worn sensor will be used to acquire non-EEG bio-signals (eg. heart activity and rate, movements, muscle activity, electrodermal activity, body temperature) Objectives - The association will be investigated between non-invasive measurable variables related to stress and sleep, semi-invasive subcutaneous EEG phenomena, and the occurrence of seizures. The predictive value of change in non-invasive variables semi-invasive subcutaneous EEG phenomena for the occurrence of seizures will be assessed. Study Duration - Up to one year for each patient. Participants may be approached during or after this study to participate in related studies. Funding - This study receives funding from the Epilepsy Foundation of America, Innovative Medicines Institute (IMI) and UNEEG medical A/S.

NCT ID: NCT04028596 Completed - Depression Clinical Trials

Measuring Blood Flow in the Brain After Epileptic Activity

SYNAPSE
Start date: December 5, 2019
Phase: Phase 2
Study type: Interventional

In this clinical trial, postictal phenomena (i.e., headache, delirium) will be investigated after administration of acetaminophen and nimodipine in depressed patients receiving electroconvulsive therapy (ECT). Postictal phenomena are thought to result from decreased cerebral blood flow and decreased oxygen concentration in the brain. It is expected that acetaminophen and nimodipine will reduce these postictal phenomena, compared to no treatment, because they target these mechanisms.

NCT ID: NCT04023851 Completed - Epilepsy Clinical Trials

Mobile Application of Seizure Diary (Brain4U) in Epilepsy Care

Start date: April 12, 2019
Phase:
Study type: Observational

The study is intended to evaluate the impact of mobile application on management and knowledge acquisition in patients with epilepsy.

NCT ID: NCT04020484 Completed - Quality of Life Clinical Trials

Making Mindfulness Matter© in Children With Epilepsy

M3Epilepsy
Start date: December 2, 2019
Phase: N/A
Study type: Interventional

Epilepsy is a debilitating condition characterized by spontaneous, unprovoked seizures. Up to 80% of children with epilepsy (CWE) may face cognitive, psychiatric, and/or behavioral comorbidities with significant unmet mental health needs. Mindfulness-based interventions may provide an ideal vector to target unmet mental healthcare needs in patients with epilepsy and their families. The investigators propose the Making Mindfulness Matter© (M3) program as an intervention to improve health related quality of life and mental-health for CWE and their parents. M3 is live-online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This pilot RCT is needed to refine the implementation of the intervention to families with a child with epilepsy, and collect information pertaining to the feasibility and effectiveness of the intervention in preparation for a subsequent multi-centred trial across Canada. Note: Due to COVID-19, the format has been modified for online delivery (from community-based) and the intervention has been restarted.

NCT ID: NCT03999827 Completed - Epilepsy Clinical Trials

A Pilot Study of the Low Glycaemic Index Diet in Adults With Epilepsy

Start date: March 19, 2019
Phase: N/A
Study type: Interventional

Many persons with epilepsy have seizures which remain uncontrolled by anti-epilepsy medications and are unsuitable for or unwilling to undergo surgical treatments for their epilepsy, or have undergone such treatments and continue to have seizures. Dietary treatments for epilepsy have been shown to be effective in children, and are probably effective in adults, but compliance with the classic ketogenic diet (KD) and to some degree also the modified Atkins diet (MAD) seems difficult for many adults. The LGI diet may be easier and in children appears to be of comparable efficacy to other dietary treatments (KD and MAD), but has been little studied in adults. This is a randomised study of immediate versus deferred LGI diet in adults with seizures incompletely controlled by anti-epilepsy medications. 12 weeks of dietary treatment in those randomised to LGI will be followed by the opportunity for the control group to undertake 12 weeks of the LGI diet.